A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
Status:
Not yet recruiting
Trial end date:
2022-05-27
Target enrollment:
Participant gender:
Summary
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the
effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a
recommended substrate of CYP3A4.